Accelerate the search for drug targets by linking genomics with proteomics

Olink has created a whitepaper which pulls together three recently published research studies highlighting the importance of linking genetic and protein expression data in the context of disease phenotypes in order to identify new, robust drug targets.

According to Olink, while many drugs are developed based on genomic findings, it’s common for these drugs to fail in the clinical phase due to their inability to provide the expected results for successful treatment. It says that this is because most drugs target proteins, not genes. Although gene transcripts encode the information to make specific proteins, the amount of gene transcript does not always correlate with the amount of protein. On the other hand, focusing on protein levels alone can’t indicate whether any biological changes are a cause or consequence of the disease being studied. This piece of intelligence explains how researchers are finding that a combined approach that integrates genomics with proteomics can overcome these challenges.

Download the whitepaper here

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free